Monocyte telomere length as a novel biomarker of macular atrophy and response to anti-VEGF therapy in age-related macular degeneration
These findings highlight monocyte telomere length as a potential biomarker for predicting macular atrophy progression and treatment outcomes in AMD. Further research is needed to confirm these associations and to explore sex/ethnic disparities in telomere length in this disease.
Authors
- A.S. Khalatyan
- D.D. Zhdanov
- K.S. Avetisov
- Yu.A. Gladilina
- Yu. Yusef
- V.G. Blinova
- A.N. Shishparenok
Institutions
- Federal State Scientific Institution Research Institute of Eye Diseases (RU)
- Institute of Biomedical Chemistry (RU)
Publication Details
- Journal
- Russian Annals of Ophthalmology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.17116/oftalma202514106152
- Primary Topic
- Telomeres, Telomerase, and Senescence
- Type
- article
- Field-Weighted Citation Impact
- 0.00